FDA Grants LX1001 Fast Track Designation for Alzheimer Disease

The FDA has granted a fast track designation to LX1001 as a potential treatment for adult patients with APOE4-associated Alzheimer disease.

CRISPR, Vertex Amend Collaboration for CTX001 in SCD, TDT

Vertex Pharmaceuticals will take the lead on worldwide development, manufacturing, and commercializing of CTX001, with payments and split economics to CRISPR Therapeutics.

Beti-Cel Withdrawn From Germany, bluebird Reduces Workforce

Betibeglogene autotemcel is being withdrawn from the German market following a breakdown in reimbursement conversations, which has resulted in bluebird reducing and reshaping its European workforce.

Avalere Report Looks at Geographic Challenges to Accessing CAR T-Cell Therapies

Given that some patients may need to travel out of state to access CAR T sites of care, some may not have a clear understanding of their insurance benefits, including requirements for out-of-state or out-of-network treatment, as well as adequate assistance with the costs of medical-related travel.

For 2021, Cell, Gene Therapies Make Prime's “Drugs to Watch” List

Three cell and gene therapies were among the drugs included in a specialty drugs pipeline forecast at the Academy of Managed Care Pharmacy 2021 meeting.

Avalere Analyst Reviews Future Change in Cancer Care Using Gene, Cell Therapies

Megan Olsen, MPH, principal at Avalere, discussed how gene and cell therapies can offer new treatment options for patients with cancer.